<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858299</url>
  </required_header>
  <id_info>
    <org_study_id>2008-07-089</org_study_id>
    <nct_id>NCT00858299</nct_id>
  </id_info>
  <brief_title>The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria</brief_title>
  <official_title>The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Chronic Kidney Diseases Patients With Persistent Proteinuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, prospective, interventional study. It does not have a control
      group. All participants will receive 160 mg valsartan for 8 weeks. Among them, the patients
      with persistent proteinuria (defined as proteinuria more than 1 g/g after 8 weeks treatment
      of valsartan) will receive 320 mg valsartan for further 16 weeks. Participants who did not
      receive any ACEI or ARB previously will have a titration period for 4 weeks (80 mg for 4
      weeks, 160 mg for 4 weeks, and then 320 mg for 16 weeks).

      The investigators will evaluate the change of urinary angiotensinogen excretion between at
      baseline, at 8 weeks, and 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percent change of urinary angiotensinogen excretion between at baseline and at 24 weeks after valsartan treatment.</measure>
    <time_frame>4 weeks of screening periods + 24 weeks of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan</intervention_name>
    <description>160 mg oral once in a day for initial 8 weeks and 320 mg, oral, once in a day for subsequent 16 weeks</description>
    <arm_group_label>valsartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic kidney disease patients with

               -  proteinuria of 1 - 10 g/day,

               -  stable and controlled blood pressure (100/60 mmHg - 160/100 mmHg),

               -  stable renal function with GFR â‰¥ 30 mL/min/ m2,

               -  diabetes or non-diabetes

        Exclusion Criteria:

          -  Uncontrolled diabetes (defined as HbA1c &gt; 9.0%)

          -  Immunosuppressive treatment within 6 months

          -  Intractable edema

          -  Hyperkalemia (&gt;5.5 mEq/L) or Hypokalemia (&lt; 3.5 mEq/L)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Goo Kim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoon-Goo Kim, Professor</last_name>
    <phone>82-2-3410-3442</phone>
    <email>ygkim26@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Nephrology, Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yoon-Goo Kim, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2009</study_first_posted>
  <last_update_submitted>March 6, 2009</last_update_submitted>
  <last_update_submitted_qc>March 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Yoon-Goo Kim</name_title>
    <organization>Division of Nephrology, Samsung Medical Center</organization>
  </responsible_party>
  <keyword>proteinuria</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>renin-angiotensin system</keyword>
  <keyword>angiotensinogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

